GlassScriptPhysician profile
George A Ford
NPI 1750525713
$14,430.12
in general payments reported to CMS, 2019-2025
43 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,179 · 2020: $3,517 · 2021: $5,225 · 2022: $316 · 2023: $252 · 2024: $590 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,542.16 | 2019-2025 | |
| Medtronic Minimed, INC. | $1,948.51 | 2019-2020 | |
| Dexcom, INC. | $338.82 | 2019-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $244.58 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $176.82 | 2020-2025 | Gvoke Hypopen |
| Pfizer INC. | $164.15 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $163.33 | 2023-2025 | |
| Ucb, INC. | $149.62 | 2019-2024 | Briviact |
| Novo Nordisk INC | $148.90 | 2019-2025 | Sogroya |
| Supernus Pharmaceuticals, INC. | $127.37 | 2019-2020 | |
| Greenwich Biosciences, INC. | $125.28 | 2020 | |
| Abbott Laboratories | $116.57 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $87.96 | 2020-2024 | |
| Arbor Pharmaceuticals, INC. | $86.74 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.32 | 2020-2025 | Gattex |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.